Hangzhou Highlightll Pharmaceutical
Privately held: no public share price
Assets
(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | TYK2/JAK1Small molecule | Parkinson's Disease | |
| Phase 1/2 | JAK1/2/3/TYK2Small molecule | Atopic Dermatitis | |
| Phase 1 | NLRP3Small molecule | Parkinson's Disease | |
| Preclinical / Unstaged | TYK2/JAK1Small molecule | PsoriasisRheumatoid ArthritisChronic Spontaneous Urticaria |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
24 September 2026Priority reviewGirocitinibChina's CDE proposes priority review for girocitinib (TLL-018) in rheumatoid arthritis
CN, NMPA (CDE) · Source ↗
Financial reports
No financial reports recorded.